What especially shook investors was the prospect that China may have closed the tech gap with the United States in AI and especially DeepSeek’s claim that it developed R1 for just $5.6 million—a far ...

Oppenheimer highlighted two major trends that are believed to be increasing public awareness and adherence to sleep treatment solutions: the proliferation of sleep wearables and GLP-1 therapies.

Although GLP-1 agonists have many advantages, they can have disadvantages. Notably, the gastrointestinal (GI) system is frequently affected by GLP1 side effects. Furthermore, minor skin responses at ...

Novo Nordisk (NYSE:NVO) A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market ...

Despite a slight miss in Q4 2024 revenues, primarily attributed to lower-than-expected inventory levels and delayed direct-to-consumer marketing efforts for its GLP-1 products, Eli Lilly has provided ...

Watertown, Mass.-based Tectonic unveiled positive interim data from the phase Ib acute hemodynamic trial with lead candidate TX-45, a long-acting, Fc-relaxin fusion protein.

As of Jan. 29, the FDA has approved more than a dozen glucagon-like peptide-1 receptor agonists for diabetes, weight loss, cardiovascular disease and other indications.

Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) drug. You inject the drug into your stomach, thigh, or upper arm.

Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast ...

Researchers project that 618,120 people will die from cancer in the US this year, which works out to about 1700 deaths per day. The American Cancer Society (ACS) has released cancer statistics for ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.